URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$43.25
−1.59%Forward multiples
Based on analyst estimates
- P/E forward
- 35.15x
- P/E 2026E
- —
- P/E 2027E
- 17.31x
- P/E 2028E
- 8.77x
- P/S forward
- 4.80x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -15.97x
- Price / sales
- 11.20x
- Price / cash flow
- -13.30x
Enterprise value
- Enterprise value
- $2.2B
- EV / sales
- 11.67x
- EV / EBITDA
- -31.14x
- EV / EBIT
- -33.04x
- Market cap
- $2.1B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026